# Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment

> **NCT01376752** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **UNICANCER** · enrollment: 415 (actual)

## Conditions studied

- Ovarian Epithelial Cancer Recurrent

## Interventions

- **PROCEDURE:** Maximal cytoreductive surgery
- **DRUG:** HIPEC

## Key facts

- **NCT ID:** NCT01376752
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2011-04-26
- **Primary completion:** 2023-01-08
- **Final completion:** 2027-05-14
- **Target enrollment:** 415 (ACTUAL)
- **Last updated:** 2025-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01376752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01376752, "Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01376752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*